Effect of Umifenovir in treatment of covid-19

Phase 3

• Conditions: covid 19.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20200523047550N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Patients diagnosed with COVID-19 infection based on PCR test for oropharyngeal and nasopharyngeal secretions or specific lung involvement in chest CT
Age over 18 years
The patient has PO tolerance
Gaining conscious satisfaction from the patient or first-degree relatives responsible for the patient
No pregnancy and breastfeeding

Exclusion Criteria

Alt more than five times normal
Renal failure
History of any drug allergies
Pregnancy and lactation
Use of antiarrhythmic drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of people improved with arbidol. Timepoint: 5, 7 and 14 days after taking Arbidol. Method of measurement: follow up with phone.